Glycine has been regarded as a poor source of nitrogen for total parenteral nutrition. Two prospective randomised cross over controlled clinical trials were undertaken to compare the efficacy of high and low glycine containing amino acid solutions in parenteraliy fed malnourished hypoalbuminaemic patients with gastrointestinal disease. In the first study (n=9), amino acid solutions in which glycine accounted for 23% and 4% of total nitrogen were compared. No statistically significant difference was found in urea nitrogen/total urinary nitrogen excretion (mean (SEM) (1.4) v 81*6 (1.7)%, p=0.31), nitrogen balance (-1.9 (2.4) v -0*6 (2.0) g/day, p=0.31) or plasma protein concentrations and blood urea nitrogen. In the second extended study (n=5), there was no significant difference in net whole body protein synthesis (+1.3 (4.7) v-0*2 (3.7) mg/kg/hour, p=0.69) or fractional (0.403 (0.070) v 0-480 (0.41)%/hour, p=0.68) and absolute albumin synthesis rates (6.0 (0.9) v 7.2 (0.06) mg/kg/hour, p=0.22), on comparing solutions of 25% and 8% glycine nitrogen. In addition, a significantly higher proportion of total urinary nitrogen comprised urea when patients received the low glycine containing amino acid source (81.4 (2.5) v 83.8 (3.2)%, p=004). It is concluded that there are no apparent short term nutritional or metabolic disadvantages to using amino acid solutions that contain up to 25% of nitrogen as glycine in total parenteral nutrition. represents less than 4% of total nitrogen." In keeping with this thinking, it has been concluded that solutions containing large amounts of glycine, as a non-essential nitrogen source, are not suitable for TPN2 and, in fact, not cost effective.'
While the importance of the quality of the nitrogen source in conserving or increasing lean body mass is well recognised,' the composition of the ideal amino acid mixture for total parenteral nutrition (TPN) solutions remains disputed.' One of the more controversial areas relates to the efficacy or otherwise of supplementing the nonessential amino acid component with the low cost readily available amino acid glycine.Ǹ itrogen balance and blood aminograms have indicated that in both hypercatabolic and postoperative patients amino acid solutions are best formulated according to the known requirements of the normal growing child.67 These in turn are comparable with the amino acid pattern of egg or human milk protein where glycine represents less than 4% of total nitrogen." In keeping with this thinking, it has been concluded that solutions containing large amounts of glycine, as a non-essential nitrogen source, are not suitable for TPN2 and, in fact, not cost effective. ' Additional arguments against using significant amounts of glycine as a nitrogen source in TPN arise from several findings. Thus , it has been reported that glycine turnover is limited to 200 mg/kg/day9 and that important renal losses of glycine occur during parenteral feeding with glycine rich solutions. 2 In one study, nitrogen balance in patients fed with high glycine containing formulations was not significantly more positive than that in unfed controls.' Hyperammonaemia in infants has also been associated with feeding a TPN solution relatively high in glycine (27%)."' Associated toxicity problems were, however, corrected by the administration of additional arginine. Finally, one theoretical objection to including large amounts of glycine in TPN amino acid solutions relates to the suggestion of Jackson and Golden" that, metabolically, glycine (along with serine, threonine, histidine, and lysine) should be considered a 'deaminating' amino acid. This supposes that with high intakes of glycine its amino nitrogen is predominantly incorporated into urea rather than contributing to protein synthesis via transamination reactions in the precursor amino acid pool.
In deference to the above arguments, there is evidence available that favours the enrichment of the non-essential amino acid component of TPN nitrogen solutions with glycine. There are data from neonates,'2 children, ' (Table  IV) . The mean daily nitrogen balance was also positive in both instances, without any statistically significant difference between high and low glycine containing solutions. The proportion of total urinary nitrogen excreted as urea was significantly lower with the high glycine containing amino acid solution compared with the low glycine solution (p=0 04).
Plasma protein concentrations and B UN
As in the first study, there was no significant difference between either the concentration of any of the plasma proteins or the BUN on day 5 of feeding the two nitrogen sources (Table V) . In the second study, in addition to the above, we were able to measure whole body protein turnover and albumin synthesis rates. We judged that these indices would provide a more sensitive means of detecting any nutritional difference between the high and low glycine containing TPN solutions. However, with the exception of a lower percentage urinary nitrogen excretion on feeding the high glycine solution, there was again no statistically significant difference between TPN solutions in any of the parameters measured.
Patients in both studies were mainly hypercatabolic, and the prescribed daily allowance of 14 g nitrogen (approximately 240 mg nitrogen/ kg/day) was judged from previous work of ours3' and others,32 to be the least required for nitrogen balance in this type of patient. Mean nitrogen balance remained negative in the first study and just positive in the second, and there was little day to day variation in total urinary nitrogen excretion (CV 3-7 to 10-6 and 6-4 to 11-3 for studies I and II respectively). Thus, the experimental design of both studies should have permitted the sensitive measurement of patient response to the quality of nitrogen infused. It has been shown that nutrient withdrawal causes a reduction in whole body protein synthesis of between 30% and 40% in preoperative patients,33 and that, in general, amino acid supply is a major controlling factor in the rate of hepatic albumin synthesis.3 36 If, therefore, glycine nitrogen had been poorly available for tissue synthesis, but channelled directly into urea, this should have been reflected in the direct and indirect parameters of nitrogen utilisation measured in the two studies. In fact, in study II the proportional urea urinary nitrogen excretion was significantly less when patients were fed the high glycine nitrogen source compared with that low in glycine (Table IV, p=0 04) .
However, it is important to point out that apart from glycine content, there were other differences in both essential and non-essential amino acid composition between the amino acid solutions compared in the two studies (Table  III) . As stated earlier, with the exception of Lmethionine and L-arginine in study I, the levels of essential amino acids, including the relatively expensive branched chain leucine, isoleucine, and valine, were higher in the low glycine containing preparations. Therefore, any influence on the efficacy of nitrogen utilisation that was dependent on essential amino acid differences rather than glycine intake would have been expected to have advantaged the low glycine containing solutions. Both high glycine containing solutions had an incomplete range of non-essential amino acids with an excess of either alanine or glutamic acid in old formulation Synthamin and Aminofusion L Forte respectively. Alanine and glutamate have both been shown to play a central role in transamination reactions37 and do not, therefore, represent the theoretical disadvantage as suppliers of nitrogen as the deaminating amino acid glycine." These two amino acids were also well represented in the Vamin preparations. Therefore, notwithstanding these limitations to the experimental design, the major variation in the concentration of glycine, if nutritionally significant, should have resulted in a measurable difference in the utilisation of the paired nitrogen sources studied.
The conclusion supported by the current studies together with previous experimental evidence,72930 namely that a high glycine content may not be deleterious to the efficacy of amino acid solutions for TPN is, we suggest, of practical importance as well as of theoretical interest. We conclude, therefore, that these two controlled clinical trials suggest that, at least in the short term, glycine nitrogen may be efficiently utilised in sick patients requiring nutritional support and that its content need not reduce the efficacy and, therefore, cost effectiveness of nitrogen solutions for TPN.
